Xstrahl Life Sciences and Sedecal Announce Collaboration to Support Pre-Clinical and Molecular Imaging Customers

Share Article

Xstrahl and Sedecal have announced their collaboration to support pre-clinical and molecular imaging customers in the USA and Canada. The distribution contract gives Xstrahl exclusive rights to sell the Argus range of Molecular imaging systems from Sedecal, enhancing its biomedical imaging technology offering.

Adrian Treverton COO of Xstrahl Life Sciences commented, “We are pleased to carry the market leading PET/CT systems in our product portfolio. Sedecal devices complement our SARRP irradiation platform that can deliver pinpoint radiation beams to orthotopic tumor models. Working with Sedecal allows us to not only make this pioneering imaging technology available to our customers, but develop software and hardware tools to enable molecular imaging device integration onto SARRP. Thus enabling translational research that mimics the patient experience.”

The new SuperArgus PET/CT family of small-animal imaging systems integrates fully functional PET, CT and MRI systems, a major breakthrough in high performance functional imaging technology for biomedical research. The SuperArgus PET/CT implements the latest in Phoswich technology and is comprised of a dual layer of LYSO and GSO crystals with a combined thickness of 15 mm, providing excellent stopping power and uncompromised resolution across the entire Field-Of-View (FOV), allowing for depth-of-interaction (DOI) identification with improved radial resolution uniformity in a small compact footprint. In addition, the SuperArgus PET/CT offers a configurable platform with three axial FOVs: 50 mm, 100 mm and 150 mm.

Sedecal’s entry into the PET/MR imaging segment combines the superior PET performance with translational MRI at 1.5T and 3.0T field strengths. With its cryogen-free superconducting magnet, the MR system offers superior field homogeneity with no special environmental conditions required. The SuperArgus imaging systems provide a truly integrated workflow, delivering fast scan times with superior image resolution, improved localization and quantifiable data with automatic fusion of PET, CT and MRI data sets after image acquisition.

Juan Manuel Arco from Sedecal adds, “We recognize that Xstrahl are the leaders in Pre-clinical irradiation solutions, making them an ideal partner for Sedecal in the USA and Canada. Their team of sales, service and applications personnel already have experience with our systems. This will result in delivering the best possible customer service in the USA and Canada.”

About Xstrahl Life Sciences
Xstrahl Life Sciences are leading scientific discovery to achieve a future where every patient receives patient centered healthcare. Xstrahl are collaborating with leading research groups to develop imaging and dose delivery research systems. These systems are enabling researchers to better understand the effect of targeted radiation. Therefore enhancing understanding of how radiation interacts with tissue, the mechanisms of DNA repair and ultimately how radiation can be used in the most effective way to improve patient centered healthcare.

About SEDECAL, Molecular Imaging Division
SEDECAL's CT, PET and PET/CT are a powerful family of tools for small-animal molecular imaging that integrate a fully functional PET and CT, a major breakthrough in high performance functional molecular imaging technology for biomedical research.

The dual modality configuration delivers faster scan times with superior image resolution, improved localization and quantifiable data.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Adrian Treverton
+44 1276537332
Email >

Alex Todman
Email >
since: 08/2010
Follow >
Visit website